Skip to main content
PeptideHackerLab

CJC-1295 (no DAC) Pharmacokinetics and Stability: Complete Analysis

How does CJC-1295 behave in the body from absorption through elimination? CJC-1295 (no DAC) has pharmacokinetic properties that directly influence its dosing and effectiveness.

As pharmacokinetics specialists, we’ve analyzed the complete ADME profile of CJC-1295 from absorption kinetics to elimination pathways.

Pharmacokinetic Overview

The pharmacokinetic profile of CJC-1295 determines its optimal administration strategy. Multiple factors influence how this peptide is absorbed, distributed, metabolized, and eliminated.

Understanding these parameters is essential for optimizing research protocols. Proper PK-informed dosing maximizes efficacy while minimizing potential adverse effects.

Key Pharmacokinetic Parameters

  • Absorption: SC depot formation; DAC version provides sustained release through albumin binding

  • Distribution: DAC: albumin-bound in plasma providing reservoir. No-DAC: systemic to pituitary

  • Metabolism: DAC: very slow release from albumin complex. No-DAC: DPP-IV resistant but serum protease susceptible

  • Elimination: DAC: very slow; albumin-dependent. No-DAC: renal excretion of fragments

  • Half-life: DAC: 6-8 days. No-DAC: 30-60 minutes

Absorption Characteristics

CJC-1295 absorption varies based on administration route and individual factors. Understanding these variables helps optimize administration protocols.

Route-Specific Absorption

Administration RouteBioavailabilityTime to PeakAbsorption Rate Subcutaneous (DAC)~85-90%1-3 hoursSlow/sustained Subcutaneous (no DAC)~85%15-30 minRapid Intravenous100%ImmediateImmediate

Factors Affecting Absorption

  • DAC vs no-DAC formulation: DAC version forms albumin complex; dramatically different PK

  • Injection volume: Larger volumes may slow initial absorption for DAC version

  • Injection site: Abdominal SC preferred for consistent absorption

  • Albumin levels: Low albumin may reduce DAC version effectiveness

Distribution and Tissue Penetration

CJC-1295 distribution throughout the body follows specific patterns. Tissue-specific accumulation contributes to the targeted effects of this peptide.

Volume of Distribution

  • Apparent Volume: DAC: restricted Vd (albumin-bound, ~7-10L). No-DAC: moderate Vd

  • Tissue Binding: DAC: primarily albumin-bound (~90%). No-DAC: moderate protein binding

  • Plasma Protein Binding: DAC: >90% (covalent albumin binding). No-DAC: ~30-40%

  • Blood-Brain Barrier: Limited direct CNS access; pituitary accessed via portal circulation

Tissue Distribution Profile

Tissue TypeConcentration RatioTime to PeakResidence Time Plasma (albumin-bound)Primary reservoir (DAC)1-3 hours6-8 days Anterior PituitaryHigh at targetVariableContinuous (DAC) Liver (via GH)IndirectVariableSustained IGF-1 Peripheral tissuesLow (peptide)VariableVia GH/IGF-1

Metabolism and Biotransformation

CJC-1295 undergoes specific metabolic processes after administration. The metabolism profile determines both duration of action and elimination pathway.

Primary Metabolic Pathways

  • Albumin dissociation (DAC): Slow release from albumin complex for sustained receptor stimulation

  • DPP-IV (resistant): Amino acid substitutions prevent primary degradation pathway

  • Non-specific proteases: Secondary degradation after albumin release or for no-DAC form

  • Renal filtration: Free peptide and fragments filtered by kidneys

Metabolite Profile

MetaboliteFormation RateActivityElimination Free CJC-1295 (from albumin)Very slow (DAC)Full (active form)Further degradation Truncated peptide fragmentsSlow-moderateMinimalRenal DAC-albumin complexVery slow degradationReservoirAlbumin turnover

Elimination Pathways

CJC-1295 is eliminated through specific clearance mechanisms. Understanding clearance helps predict duration of action and accumulation potential.

Clearance Components

  • Total Clearance: DAC: very low (~0.1 L/h). No-DAC: moderate (~15-20 mL/min/kg)

  • Renal Clearance: Minor for DAC (albumin-protected); primary for no-DAC

  • Hepatic Clearance: Minor contribution

  • Other Routes: Albumin turnover for DAC (~15-20 day albumin half-life)

Half-life Analysis

PhaseHalf-lifeElimination ConstantSignificance Absorption/bindingDAC: 1-3h to albumin binding. No-DAC: 10-15 minVariableFormation of active complex (DAC) or distribution (no-DAC) EliminationDAC: 6-8 days. No-DAC: 30-60 minDAC: 0.004 h⁻¹. No-DAC: 0.7-1.4 h⁻¹Determines dosing frequency GH/IGF-1 effectDAC: 7-14 days sustained. No-DAC: 2-4 hoursSustained (DAC)Clinical effect duration

Chemical Stability

The chemical stability of CJC-1295 determines proper storage and handling requirements. Peptide stability is influenced by temperature, pH, light, and humidity.

Stability Under Different Conditions

ConditionTemperaturepH RangeStability PeriodDegradation Rate Lyophilized (powder)-20°C to 4°CN/A (solid)24-36 months Reconstituted (refrigerated)2-8°C6.5-7.54-6 weeks2-5% per week Reconstituted (room temp)20-25°C6.5-7.548-72 hours5-10% per day Extreme conditions>37°C9>20% per day

Degradation Pathways

  • Hydrolysis: Peptide bond cleavage by water, accelerated at extreme pH

  • Oxidation: Methionine and cysteine residue oxidation by reactive oxygen species

  • Deamidation: Asparagine and glutamine side chain modification at elevated pH

  • Aggregation: Intermolecular association at high concentrations or elevated temperatures

Formulation Considerations

Proper formulation of CJC-1295 ensures stability and consistent bioavailability. Peptides require careful formulation to maintain structural integrity.

Stabilization Strategies

  • pH Optimization: Maintain pH 6.5-7.5 for optimal stability; avoid extremes

  • Excipient Selection: Mannitol or trehalose as lyoprotectants during freeze-drying

  • Buffer Systems: Phosphate or acetate buffer systems at physiological pH

  • Antioxidants: Methionine or ascorbic acid to prevent oxidative degradation

Storage Recommendations

  • Temperature: Lyophilized: -20°C to 4°C; Reconstituted: 2-8°C

  • Light Protection: Store in amber vials or protect from direct light exposure

  • Humidity Control: Keep lyophilized product in sealed container with desiccant

  • Container Type: Type I borosilicate glass vials with rubber stoppers

  • Shelf Life: 24-36 months lyophilized; 4-6 weeks reconstituted at 2-8°C

Bioanalytical Methods

Quantification of CJC-1295 in biological matrices requires specialized analytical methods. Validated methods ensure accurate pharmacokinetic parameter determination.

Quantification Methods

MethodDetection LimitPrecisionAccuracySample Type LC-MS/MS0.1-1 ng/mLCV ±15%Plasma/serum ELISA1-10 ng/mLCV ±20%Plasma/serum RIA0.5-5 ng/mLCV ±18%Plasma/tissue

Population Pharmacokinetics

Population pharmacokinetics of CJC-1295 reveal important sources of variability. Understanding these covariates helps personalize dosing approaches.

Covariates Affecting PK

  • Age: Reduced clearance in elderly; may require 20-30% dose reduction after age 65

  • Sex: Minimal sex-based differences in PK parameters for most peptides

  • Body Weight: Body weight influences volume of distribution; consider weight-based dosing for extremes

  • Renal Function: Impaired renal function reduces clearance proportionally; adjust dose in CKD

  • Hepatic Function: Mild hepatic impairment: minimal effect; severe: consider dose reduction

Population Parameters

ParameterPopulation MeanInterindividual CV%Residual Variability Clearance (CL)Moderate30-45%15-25% Volume (Vd)Moderate-Large25-40%10-20% Absorption (Ka)Rapid35-50%20-30%

Drug-Drug Interactions

Drug-drug interactions with CJC-1295 have been evaluated in limited research contexts. Most interactions are pharmacodynamic rather than pharmacokinetic in nature.

Interaction Potential

Interaction TypeMechanismClinical SignificanceManagement Hormonal medicationsPharmacodynamic overlap with endocrine pathwaysModerateMonitor hormone levels; adjust doses as needed Anti-inflammatory drugsPotential additive anti-inflammatory effectsLowGenerally safe; monitor for enhanced effects Other peptidesSynergistic or additive pathway activationLow-ModerateConsider reduced doses when combining; monitor response

Clinical Implications

The PK profile of CJC-1295 directly informs optimal dosing strategies. Understanding absorption, distribution, and elimination guides protocol design.

Dosing Considerations

  • Optimal Dosing Interval: Based on elimination half-life and desired trough levels

  • Loading Dose: Not typically required; steady-state achieved within 3-5 half-lives

  • Steady State: Achieved within 3-5 elimination half-lives of repeated dosing

  • Accumulation Ratio: Minimal accumulation with appropriate dosing intervals

Regulatory Considerations

Regulatory frameworks require comprehensive PK characterization for peptide compounds. Current PK data for CJC-1295 represents research-grade characterization.

Regulatory Status

  • FDA Guidance: Research compound; not subject to formal FDA PK requirements

  • EMA Requirements: Not currently under EMA evaluation; research use only

  • ICH Guidelines: ICH M3/S6 guidelines would apply for formal development

  • Data Requirements: Comprehensive ADME studies required for any therapeutic development pathway

Future Research Directions

Several areas of PK research for CJC-1295 warrant further investigation:

  • Comprehensive human PK studies with validated bioanalytical methods

  • Population PK modeling to identify optimal dose individualization strategies

  • Drug-drug interaction studies with commonly used medications

  • Novel formulation development for improved stability and delivery

Conclusion

For a comprehensive overview of this compound, see our complete .

The pharmacokinetic profile of CJC-1295 supports its current research applications. Understanding ADME properties is essential for safe and effective research protocols.

Professional oversight ensures proper PK-informed dosing decisions. Regular monitoring helps verify expected PK behavior in individual subjects.

Frequently Asked Questions

1. How long does CJC-1295 stay in the system?

The plasma half-life of CJC-1295 is DAC: 6-8 days. No-DAC: 30-60 minutes. However, biological effects may persist longer than plasma presence due to downstream signaling cascades.

2. What is the best route of administration for CJC-1295?

Subcutaneous (DAC) injection provides ~85-90% bioavailability with peak levels at 1-3 hours, making it the most common research route.

3. Does CJC-1295 accumulate with repeated dosing?

With appropriate dosing intervals based on the elimination half-life, minimal accumulation occurs. Steady-state is typically achieved within 3-5 half-lives.

4. How should CJC-1295 be stored?

Lyophilized powder should be stored at -20°C to 4°C (stable 24-36 months). Once reconstituted, store at 2-8°C and use within 4-6 weeks.

5. Do age or health conditions affect CJC-1295 pharmacokinetics?

Yes, renal and hepatic impairment can reduce clearance, and elderly individuals may require dose adjustments. Body weight also influences volume of distribution.